The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABEO's RSI Oscillator exited the oversold zone, of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABEO advanced for three days, in of 243 cases, the price rose further within the following month. The odds of a continued upward trend are .
ABEO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on December 11, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on ABEO as a result. In of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ABEO turned negative on December 09, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at .
ABEO moved below its 50-day moving average on December 03, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ABEO crossed bearishly below the 50-day moving average on November 18, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABEO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABEO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.414) is normal, around the industry mean (14.529). P/E Ratio (0.000) is within average values for comparable stocks, (87.563). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.739). ABEO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (30.303) is also within normal values, averaging (255.281).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
a developer of pharmaceutical products
Industry Biotechnology
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
DTCCX | 14.45 | 0.19 | +1.33% |
BNY Mellon Sust US Equity C | |||
PAHUX | 7.83 | 0.09 | +1.16% |
PGIM Jennison NextGeneration Glb Opps Z | |||
TIDDX | 62.68 | 0.44 | +0.71% |
T. Rowe Price International Discovery I | |||
GTDDX | 33.09 | 0.23 | +0.70% |
Invesco EQV Emerging Markets All Cap A | |||
AFGPX | 15.97 | 0.08 | +0.50% |
Alger International Opportunities B |
A.I.dvisor tells us that ABEO and AXON have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ABEO and AXON's prices will move in lockstep.
Ticker / NAME | Correlation To ABEO | 1D Price Change % | ||
---|---|---|---|---|
ABEO | 100% | +1.24% | ||
AXON - ABEO | 31% Poorly correlated | +2.60% | ||
SCPH - ABEO | 29% Poorly correlated | +2.42% | ||
XNCR - ABEO | 29% Poorly correlated | +0.50% | ||
AMRN - ABEO | 28% Poorly correlated | -1.18% | ||
GLPG - ABEO | 28% Poorly correlated | +1.48% | ||
More |